Genmab A/S reports results for the quarter ended in September 30 - Earnings Summary

• Genmab A/S GMAB.OQ reported quarterly adjusted earnings of 29 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 47 cents. The mean expectation of five analysts for the quarter was for earnings of 35 cents per share.

• Revenue rose 17.8% to $815.85 million from a year ago; analysts expected $836.41 million.

• Genmab A/S's reported EPS for the quarter was 29 cents​.

• The company reported quarterly net income of $186.44 million.

• Genmab A/S shares had fallen by 6.7% this quarter and lost 28.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.9% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Genmab A/S is 38.00

This summary was machine generated from LSEG data November 6 at 11:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)